Severe Cardiac Dysfunction and Death Caused by Arrhythmogenic Right Ventricular Cardiomyopathy Type 5 Are Improved by Inhibition of Glycogen Synthase Kinase-3β
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Background: Arrhythmogenic cardiomyopathy/arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited cardiac disease characterized by fibrofatty replacement of the myocardium, resulting in heart failure and sudden cardiac death. The most aggressive arrhythmogenic cardiomyopathy/ARVC subtype is ARVC type 5 (ARVC5), caused by a p.S358L mutation in TMEM43 (transmembrane protein 43). The function and localization of TMEM43 are unknown, as is the mechanism by which the p.S358L mutation causes the disease. Here, we report the characterization of the first transgenic mouse model of ARVC5. Methods: We generated transgenic mice overexpressing TMEM43 in either its wild-type or p.S358L mutant (TMEM43-S358L) form in postnatal cardiomyocytes under the control of the α-myosin heavy chain promoter. Results: We found that mice expressing TMEM43-S358L recapitulate the human disease and die at a young age. Mutant TMEM43 causes cardiomyocyte death and severe fibrofatty replacement. We also demonstrate that TMEM43 localizes at the nuclear membrane and interacts with emerin and β-actin. TMEM43-S358L shows partial delocalization to the cytoplasm, reduced interaction with emerin and β-actin, and activation of glycogen synthase kinase-3β (GSK3β). Furthermore, we show that targeting cardiac fibrosis has no beneficial effect, whereas overexpression of the calcineurin splice variant calcineurin Aβ1 results in GSK3β inhibition and improved cardiac function and survival. Similarly, treatment of TMEM43 mutant mice with a GSK3β inhibitor improves cardiac function. Finally, human induced pluripotent stem cells bearing the p.S358L mutation also showed contractile dysfunction that was partially restored after GSK3β inhibition. Conclusions: Our data provide evidence that TMEM43-S358L leads to sustained cardiomyocyte death and fibrofatty replacement. Overexpression of calcineurin Aβ1 in TMEM43 mutant mice or chemical GSK3β inhibition improves cardiac function and increases mice life span. Our results pave the way toward new therapeutic approaches for ARVC5.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Garcia-Gras, E. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27751 · Cited by 623
Sala, L., van Meer, B. J., Tertoolen, L. G. J., Bakkers, J., Bellin, M., Davis, R. P., Denning, C., Dieben, M. A. E., Eschenhagen, T., Giacomelli, E., et al. (2018) · Circulation Research · doi:10.1161/circresaha.117.312067 · Cited by 416
Autophagy in cardiovascular biology
Lavandero, S., Chiong, M., Rothermel, B. A., & Hill, J. A. (2015) · Journal of Clinical Investigation · doi:10.1172/jci73943 · Cited by 331
Li, J., Patel, V. V., Kostetskii, I., Xiong, Y., Chu, A. F., Jacobson, J. T., Yu, C., Morley, G. E., Molkentin, J. D., & Radice, G. L. (2005) · Circulation Research · doi:10.1161/01.res.0000181132.11393.18 · Cited by 223
Pilichou, K., Remme, C. A., Basso, C., Campian, M. E., Rizzo, S., Barnett, P., Scicluna, B. P., Bauce, B., van den Hoff, M. J. B., de Bakker, J. M. T., et al. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20090641 · Cited by 210
Gomes, J., Finlay, M., Ahmed, A. K., Ciaccio, E. J., Asimaki, A., Saffitz, J. E., Quarta, G., Nobles, M., Syrris, P., Chaubey, S., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehr472 · Cited by 194
Central role for GSK3β in the pathogenesis of arrhythmogenic cardiomyopathy
Chelko, S. P., Asimaki, A., Andersen, P., Bedja, D., Amat-Alarcon, N., DeMazumder, D., Jasti, R., MacRae, C. A., Leber, R., Kleber, A. G., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.85923 · Cited by 180
van Spreeuwel, A. C. C., Bax, N. A. M., van Nierop, B. J., Aartsma-Rus, A., Goumans, M.-J. T. H., & Bouten, C. V. C. (2017) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-017-9737-1 · Cited by 38
Cited by
Molecular pathology of laminopathies
Shin, J.-Y., & Worman, H. J. (2022) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-042220-034240 · Cited by 130
Lin, Y.-N., Mesquita, T., Sanchez, L., Chen, Y.-H., Liu, W., Li, C., Rogers, R., Wang, Y., Li, X., Wu, D., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab419 · Cited by 83
Myocardial Inflammation as a Manifestation of Genetic Cardiomyopathies: From Bedside to the Bench
Peretto, G., Sommariva, E., Di Resta, C., Rabino, M., Villatore, A., Lazzeroni, D., Sala, S., Pompilio, G., & Cooper, L. T. (2023) · Biomolecules · doi:10.3390/biom13040646 · Cited by 37
Gao, S., Puthenvedu, D., Lombardi, R., & Chen, S. N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176320 · Cited by 28
“AKT was found inhibited, leading to GSK-3β activation and consequent inhibition of β-catenin activity in this mouse model [23].”
BackgroundHistopathological Features and Protein Markers of Arrhythmogenic Cardiomyopathy
Bueno-Beti, C., & Asimaki, A. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.746321 · Cited by 12
Metadata
- Authors
- Padrón-Barthe, L., Villalba-Orero, M., Gómez-Salinero, J. M., Domínguez, F., Román, M., Larrasa-Alonso, J., Ortiz-Sánchez, P., Martínez, F., López-Olañeta, M., Bonzón-Kulichenko, E., Vázquez, J., Martí-Gómez, C., Santiago, D. J., Prados, B., Giovinazzo, G., Gómez-Gaviro, M. V., Priori, S., Garcia-Pavia, P., & Lara-Pezzi, E.
- Venue
- Circulation
- Published
- 2019-10
- Volume
- 140
- Issue
- 14
- Pages
- 1188-1204
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2971413020
- Cited by
- 91
- References
- 8
- FWCI
- 7.01
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.